Stifel Financial’s Aquestive Therapeutics AQST Stock Holding History

Stifel Financial’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Sell	359,903 -9,825	-3%	-$39.9K	﹤0.01%	2163
2025 Q4	$2.39M	Buy	369,728 +3,300	+0.9%	+$20.6K	﹤0.01%	1809
2025 Q3	$2.05M	Sell	366,428 -7,800	-2%	-$33.7K	﹤0.01%	1897
2025 Q2	$1.24M	Sell	374,228 -900	-0.2%	-$2.58K	﹤0.01%	2187
2025 Q1	$1.09M	Sell	375,128 -23,433	-6%	-$70.9K	﹤0.01%	2167
2024 Q4	$1.42M	Buy	398,561 +302,617	+315%	+$1.4M	﹤0.01%	2020
2024 Q3	$478K	Sell	95,944 -301,538	-76%	-$1.17M	﹤0.01%	2708
2024 Q2	$1.03M	Buy	397,482 +7,600	+2%	+$25.4K	﹤0.01%	2140
2024 Q1	$1.66M	Buy	+389,882	New	+$1.3M	﹤0.01%	1857

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stifel Financial's AQST Position: Q1 2026 in Review

Stifel Financial reduced its Aquestive Therapeutics (AQST) stake by 2.7% in Q1 2026, selling an estimated $39.9K and leaving 359,903 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2163.

Stifel Financial first reported a position in AQST in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.39M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Stifel Financial held 359,903 shares of Aquestive Therapeutics worth $1.49M as of Q1 2026.
Stifel Financial sold 9,825 Aquestive Therapeutics shares in Q1 2026, an estimated $39.9K.
Aquestive Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #2163 holding.
Stifel Financial first reported a position in Aquestive Therapeutics in Q1 2024 and has held it in 9 quarters since.
Stifel Financial's Aquestive Therapeutics position peaked at $2.39M in Q4 2025.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.